North Capital Inc. Acquires New Holdings in Edwards Lifesciences Corporation (NYSE:EW)

North Capital Inc. acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,244 shares of the medical research company's stock, valued at approximately $380,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences in the fourth quarter worth $27,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth $29,000. Global X Japan Co. Ltd. boosted its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC increased its holdings in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.3%

EW stock traded down $0.25 during trading on Friday, hitting $76.77. The company had a trading volume of 1,679,364 shares, compared to its average volume of 5,238,956. The firm has a 50-day moving average price of $76.10 and a 200-day moving average price of $73.26. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.03 billion, a price-to-earnings ratio of 10.97, a PEG ratio of 3.87 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $0.66 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian sold 5,980 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the transaction, the chief executive officer directly owned 58,284 shares in the company, valued at $4,366,054.44. This represents a 9.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president owned 47,206 shares of the company's stock, valued at $3,295,450.86. The trade was a 16.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,648 shares of company stock worth $2,998,866. 1.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Piper Sandler increased their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Truist Financial lowered their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Finally, Canaccord Genuity Group increased their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and an average target price of $80.20.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.